Month: September 2026

Yatra Board Has Unanimously Recommended That Yatra Shareholders NOT Tender Their Shares Into Magna’s Offer

Yatra Board Has Unanimously Recommended That Yatra Shareholders NOT Tender Their Shares Into Magna’s Offer

Agomab Therapeutics today announced positive results of the Phase 1 study of AGMB-447 in IPF patients.

Agomab Therapeutics today announced positive results of the Phase 1 study of AGMB-447 in IPF patients.

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

– Acquired Significantly Below Replacement Cost –
– Property Provides Long-Term Repositioning Opportunity –
– 2026 Year-to-Date Investments Total $334 Million –

RCI BANQUE LAUNCHES A DUAL-TRANCHE BOND ISSUE IN EURO: 750 MILLION MATURING IN 2031 AND 500 MILLION MATURING IN 2033

RCI BANQUE LANCE UNE ÉMISSION OBLIGATAIRE EN EUROS À DOUBLE TRANCHE : 750 MILLIONS D’EUROS À ÉCHÉANCE 2031 ET 500 MILLIONS D’EUROS À ÉCHÉANCE 2033

The Global Multi-Agent AI Platforms Market is segmented by Component, Platform Type, Deployment, Organization Size, End-Use, Region and Forecast 2026-2035

Ahead of Canada’s National Day for Truth and Reconciliation, two aviation ministries highlight an approach built on invitation, long-term commitment, and relationships that extend far beyond the flight.

Ahead of Canada’s National Day for Truth and Reconciliation, two aviation ministries highlight an approach built on invitation, long-term commitment, and relationships that extend far beyond the flight.

New communities extend Inspire’s commitment to creating safe, supportive spaces for women to connect through every stage of their health journey.

New communities extend Inspire’s commitment to creating safe, supportive spaces for women to connect through every stage of their health journey.

Sarcomatrix Therapeutics Provides Update on Board Expansion and Rare Disease Programs

The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.

The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.

Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition

VICTORIA, Seychelles, Sept. 14, 2026 (GLOBE NEWSWIRE) — Excent Capital has launched its new website, introducing a redesigned experience for traders, clients and partners worldwide.

U.S. Renal Denervation Devices Market to Reach USD 2.01 Billion and Europe USD 1.13 Billion by 2035 as Ultrasound Catheters, CMS Coverage Review, and Expanding Indications Drive Growth.

U.S. Renal Denervation Devices Market to Reach USD 2.01 Billion and Europe USD 1.13 Billion by 2035 as Ultrasound Catheters, CMS Coverage Review, and Expanding Indications Drive Growth.

MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) — ReleasePad, a Changelog Tool, today launched a Model Context Protocol (MCP) server that lets AI coding agents such as Claude, Codex, Grok and other LLM’s draft, publish and analyze product changelogs directly from a conversation. Release notes are the step most teams skip: the feature ships, the announcement waits, and customers never hear about it. With the MCP server, the same coding agent a developer already works with can close that gap in a sentence: “Look at what we merged this week, draft a release note for customers, and leave it as a draft for me.”

Communiqué de Presse

THE DISSEMINATION, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IS NOT AUTHORIZED IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER COUNTRY WHERE SUCH COMMUNICATION WOULD VIOLATE APPLICABLE REGULATIONS

LA DIFFUSION, LA PUBLICATION OU LA DISTRIBUTION DE CE COMMUNIQUÉ DE PRESSE, EN TOUT OU EN PARTIE, DIRECTEMENT OU INDIRECTEMENT, N’EST PAS AUTORISÉE AUX ÉTATS-UNIS, EN AUSTRALIE, AU CANADA, AU JAPON OU DANS TOUT AUTRE PAYS OÙ UNE TELLE COMMUNICATION VIOLERAIT LES RÉGLEMENTATIONS APPLICABLES